Introduction
============

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common chronic childhood-onset psychiatric disorders, with an estimated global prevalence of 5.9%--7.1% among children/adolescents and 1.2%--7.3% among adults.[@b1-ndt-13-1741]--[@b3-ndt-13-1741] ADHD was initially considered a childhood disorder that dissipated by adolescence or adulthood[@b4-ndt-13-1741]; however, it is now defined as a chronic disorder that is reported to persist into adulthood in \~30%--80% of those who retrospectively reported childhood ADHD.[@b5-ndt-13-1741]--[@b7-ndt-13-1741] Children with ADHD are often characterized as hyperactive, and adults with ADHD are more likely to experience inner restlessness, an inability to relax, overtalkativeness, inattention, poor planning, and impulsivity.[@b6-ndt-13-1741],[@b8-ndt-13-1741],[@b9-ndt-13-1741] ADHD has a significant impact on psychosocial functioning (lower level of education, higher level of unemployment, and higher rates of unsuccessful marriages, criminality, and road traffic accidents).[@b10-ndt-13-1741],[@b11-ndt-13-1741]

Treatment strategies for ADHD include both pharmacological and psychological therapies aimed to improve the core symptoms of ADHD (hyperactivity, impulsivity, and inattention) and associated functional impairments. Psychostimulants, including methylphenidate (MPH) and amphetamine-based treatments, are the most commonly prescribed pharmacological treatments for adults and children with ADHD.[@b12-ndt-13-1741]--[@b14-ndt-13-1741] Despite being one of the mainstay treatments for ADHD, MPH use remains off-label for adults in some countries.[@b15-ndt-13-1741],[@b16-ndt-13-1741]

Based on the efficacy data from randomized controlled trials and meta-analyses, MPH is now a widely accepted treatment for ADHD.[@b17-ndt-13-1741],[@b18-ndt-13-1741] Moreover, MPH is also reported to reduce the social, health, economical, and functional impairments experienced by ADHD patients.[@b6-ndt-13-1741],[@b19-ndt-13-1741]--[@b22-ndt-13-1741] However, response to MPH treatment varies significantly between patients.[@b17-ndt-13-1741],[@b23-ndt-13-1741],[@b24-ndt-13-1741] Thus, certain patients may not achieve adequate symptom control, while others are unable to tolerate the same dose of MPH because of adverse events (AEs).[@b25-ndt-13-1741]--[@b28-ndt-13-1741] Recent guidelines recommend tailoring MPH dosage to individual patient's needs (referred to as dose optimization, dose individualization, or flexible dose; [Table 1](#t1-ndt-13-1741){ref-type="table"}).[@b29-ndt-13-1741]--[@b31-ndt-13-1741] However, no head-to-head studies have directly compared benefits of flexible-versus fixed-dose treatment regimens.

The present review examines the recommendations for dose optimization in recent ADHD treatment guidelines, and the use of dose optimization in randomized clinical trials, as well as naturalistic studies. In addition, previously unpublished analysis from the largest MPH modified-release long-acting (MPH-LA) trial is presented to highlight the potential efficacy and safety benefits of dose optimization versus randomized fixed-dose regimens.

Dose optimization in clinical practice
======================================

Dose optimization is used routinely in general medicine and psychiatry to ensure optimal clinical effect, while minimizing the risk of AEs. Dose optimization is common for almost all psychotropic medications and may be crucial, particularly when considering clinical dose--response relationships with high interindividual variation, such as the use of stimulants for treatment of ADHD.[@b32-ndt-13-1741],[@b33-ndt-13-1741] Various factors can influence the need for dose optimization including genetic variability, patient weight, age, sex, drug-induced tolerance, and interactions with other medications or medical conditions. The length of time required and the method used to optimize dosage can vary extensively between pharmacological treatments.

MPH has a wide interindividual variability in dose response. In a meta-analysis of 18 randomized controlled trials, Castells et al found a positive dose--response relationship between MPH and ADHD symptoms in adults; however, in large clinical trials investigating a range of various MPH formulations, no dose--response relationship was found in adults with ADHD.[@b17-ndt-13-1741],[@b34-ndt-13-1741]--[@b36-ndt-13-1741]

Moreover, the dose--response relationship of MPH has also been debated in pediatric studies. Reportedly, a dose--response relationship was observed with osmotic-controlled release oral delivery system methylphenidate (OROS-MPH) in children with combined-type ADHD, whereas such a relationship was not noted in children with ADHD of a predominantly inattentive subtype.[@b37-ndt-13-1741] Furthermore, the association between dose optimization and weight remains inconclusive; some studies have reported no relationship between the final optimal dose and body weight, while others have indicated weight as a reliable clinical parameter for dose optimization.[@b38-ndt-13-1741]--[@b40-ndt-13-1741] Douglas et al reported a linear dose--response relationship between dose (0.15, 0.30, and 0.60 mg/kg) and improvements in performance.[@b41-ndt-13-1741] This substantial intersubject variability has prompted the use of dose optimization in ADHD management.

MPH dose optimization: current recommendations
==============================================

A number of European guidelines, including Swedish ADHD and National Institute for Health and Care Excellence (NICE) guidelines, recommend MPH as the first-line pharmacological treatment for adults and children with severe impairment (or moderate impairment but nonresponsive to nonpharmacological interventions).[@b29-ndt-13-1741],[@b42-ndt-13-1741] MPH is available as an immediate-release (MPH-IR) tablet and in a variety of modified-release formulations including long-acting formulations, topical patches, and extended-release formulations.[@b43-ndt-13-1741]--[@b48-ndt-13-1741] In accordance with most ADHD treatment guidelines (eg, NICE), product guidelines recommend that MPH-naïve patients must be initially treated at low doses, and the doses should be increased on an individual basis until optimal response is achieved without an AE.[@b43-ndt-13-1741]--[@b48-ndt-13-1741] Several ADHD treatment guidelines recommend that long- or short-acting stimulant medications should be prescribed based on individual patient needs.[@b16-ndt-13-1741],[@b29-ndt-13-1741],[@b49-ndt-13-1741] However, other guidelines recommend the use of long-acting stimulants as first-line treatment.[@b30-ndt-13-1741]

European, Australasian, and North American ADHD guidelines support the use of pharmacotherapy for children with severe ADHD, children with moderate ADHD who are nonresponsive to behavioral therapy, and adults with moderate or severe ADHD. Collectively, these guidelines also highlight the need for dose titration and optimization of pharmacological therapy ([Table 1](#t1-ndt-13-1741){ref-type="table"}).[@b6-ndt-13-1741],[@b29-ndt-13-1741]--[@b31-ndt-13-1741] Moreover, the Canadian Attention Deficit Hyperactivity Disorder Resource Alliance guidelines recommend regular follow-ups to ensure treatment efficacy and tolerability.[@b30-ndt-13-1741] It is important to note that treatment guidelines vary regarding how dose optimization should be managed. Certain guidelines define optimal treatment as the dose above which there is no further improvement, whereas other guidelines recommend using the lowest dose necessary to achieve optimal therapeutic response.[@b30-ndt-13-1741],[@b49-ndt-13-1741] Therefore, methods of optimization tend to vary between clinical studies. In certain trials, doses have been increased until the patient responds or until the maximum dose is reached.[@b50-ndt-13-1741] In other studies, doses have been increased until the occurrence of an AE, whereby the dose was then decreased to the previously tolerated dose.[@b34-ndt-13-1741] Another way to find an optimal dose is the use of a blinded N=1 strategy, where different doses are given to the patient in a blinded manner to find the best balance between symptom control and possible AEs. Although blinded N=1 trials are a promising way of dose optimization at the individual patient level, they are not widely used as they are considered time-consuming and no standards are established on possible ranges, duration of drug or placebo exposure, and titration schedules on the N=1 level.

Despite a high level of consistency between national and international treatment guidelines ([Table 1](#t1-ndt-13-1741){ref-type="table"}) and MPH product labels, in the real-world clinical treatment of ADHD, health care providers may not adhere to these recommendations.[@b43-ndt-13-1741]--[@b48-ndt-13-1741] Goodman et al[@b51-ndt-13-1741] reported that a high proportion of family physicians are not confident with diagnosing and treating adult ADHD. A survey of 1,216 primary care physicians (PCPs) revealed that 31% of PCPs rated themselves as "not confident" when diagnosing adult ADHD, and 36% were "not confident" regarding treatment. In the same survey, psychiatrists were more confident with diagnosis and treatment of ADHD. Furthermore, a recently published US study of over 1,500 patient charts from 188 pediatricians across 50 different practices, from August 2002 through December 2012, demonstrated that community-based ADHD care was not consistent with the guidelines.[@b52-ndt-13-1741] Overall, only 47.4% of children prescribed medication had contact (phone contact or visit) with their pediatrician within the first month of their prescription, and parent- and teacher-rating scales were rarely collected to monitor treatment response or side effects. These data indicate the need for improved awareness of how best to manage pharmacological dose titration to achieve optimal dosage.

Dose optimization in clinical trials and naturalistic studies
=============================================================

MPH dose optimization in clinical trials
----------------------------------------

Although MPH dose optimization is recommended in the ADHD treatment guidelines, and clinical trials report flexible-dose therapy, fixed-dose therapy, or a combination of both, analyses of the clinical benefits of dose optimization versus fixed-dose regimens for patients are limited. A recent meta-regression analysis of 18 randomized, placebo-controlled studies compared the outcomes of MPH clinical trials that included flexible-dose regimens (12 studies; 1,327 adults with ADHD) to those that included fixed-dose regimens (6 studies; 718 adults with ADHD).[@b17-ndt-13-1741] However, none of the trials included in their analysis directly compared fixed-versus flexible-dose regimens.

Recent randomized, controlled ADHD trials that have incorporated a flexible-dose regimen have reported that a range of MPH doses are required to effectively treat patients.[@b38-ndt-13-1741],[@b50-ndt-13-1741],[@b53-ndt-13-1741]--[@b56-ndt-13-1741] In a randomized, placebo-controlled trial ([Figure 1](#f1-ndt-13-1741){ref-type="fig"}), Huss et al[@b53-ndt-13-1741] reported that several doses of MPH-LA (40, 60, and 80 mg) were determined to be optimal for a similar number of ADHD patients (n=152, n=177, and n=160, respectively). Further analysis of the MPH-LA study data showed that this was irrespective of the initial dose administered during Period 1 ([Figure 2](#f2-ndt-13-1741){ref-type="fig"}; previously unpublished data). Similarly, other clinical trials have also reported that multiple doses of MPH are required for adequate treatment of adults and children with ADHD. Buitelaar et al[@b54-ndt-13-1741] reported that a range of OROS-MPH doses are required; overall, 7.9% of patients completed the study on 18 mg of OROS-MPH, 29.3% on 36 mg, 34.4% on 54 mg, 19.8% on 72 mg, and 8.7% on 90 mg. In another study wherein children and adolescents treated with MPH extended-release, a number of doses were also required for optimal treatment[@b38-ndt-13-1741]; overall, 27.7% of pediatric patients had received a final open-label dose of 30 mg, 25.2% had 40 mg, 17.8% had 50 mg, 16.8% had 20 mg, 8.9% had 60 mg, 2.0% had 15 mg, and 1.5% had 10 mg. The need for multiple doses of MPH to achieve effective symptom control further highlights the importance of an individualized or tailored treatment approach for ADHD. Recently, Chermá et al[@b40-ndt-13-1741] reported a large variation in the optimal treatment dose of 59 patients with ADHD; however, blood sample analysis revealed that the median daily dose per body weight was similar (\~1.0 mg/kg). As per the available literature, genetic differences may lead to significant variability in pharmacokinetic profiles across the day at an individual level, which may result in the large variation observed.[@b58-ndt-13-1741]

MPH dose optimization in naturalistic and open-label extension studies
----------------------------------------------------------------------

Recent noninterventional or naturalistic studies have examined the efficacy and/or safety of MPH in children, adolescents, or adults with ADHD.[@b57-ndt-13-1741] Fredriksen et al conducted a naturalistic study to assess the 1-year efficacy of ADHD treatment regimens in adults with ADHD.[@b59-ndt-13-1741] All patients received MPH as the first-line pharmacological treatment in addition to psychosocial interventions. The study was conducted at a specialized outpatient clinic in Norway and involved a 6-week MPH titration phase (up to 60 mg/day) followed by a dose-optimization phase (maximum dose 120 mg/day). Under these real-world conditions, \~70% of patients completed the 1-year study phase without discontinuing pharmacological treatment: 128 patients continued to receive MPH, 25 had switched to dextroamphetamine, and 10 had switched to atomoxetine. In line with randomized, controlled clinical trials, AEs and lack of efficacy were reported as the most common reasons for treatment discontinuation.[@b59-ndt-13-1741],[@b60-ndt-13-1741] Moreover, the study revealed that approximately half of the patients preferred immediate-release MPH over extended-release formulations, highlighting the need for clinicians to consider alternative MPH formulations on an individual patient basis.

Cortese et al have recently published long-term MPH-IR safety data from the Italian National ADHD Registry[@b61-ndt-13-1741]; similar to the study conducted by Fredriksen et al, treatment was individualized based on clinical response and tolerability (maximum dose 0.6 mg/kg/dose).[@b59-ndt-13-1741] The safety profile was favorable as 25.9% of MPH-treated patients had experienced at least one mild AE and 4.5% had experienced at least one severe AE.[@b61-ndt-13-1741]

Open-label extension studies of randomized controlled trials have provided evidence regarding the long-term benefits and safety of dose-optimized MPH treatment.[@b53-ndt-13-1741],[@b63-ndt-13-1741]--[@b65-ndt-13-1741] Buitelaar et al evaluated the long-term efficacy and tolerance of OROS-MPH, wherein no evidence of withdrawal or rebound was reported after treatment discontinuation.[@b64-ndt-13-1741] As previously reported in randomized controlled trials, the most common reason reported for treatment discontinuation was AE.[@b60-ndt-13-1741] Ginsberg et al reported a lower rate (2.3%) of AE-induced discontinuation during the extension phase of the MPH-LA study compared with other open-label extension studies such as OROS-MPH (18.5%).[@b55-ndt-13-1741],[@b63-ndt-13-1741] They suggested that this was because of the use of flexible-dose regimens, which was allowed during the extension phase of the study.

MPH-LA clinical trial: design and analysis
==========================================

Huss et al designed the only clinical trial (NCT01259492) including both fixed- and flexible-dose phases that directly investigated the benefits of flexible-dose regimens.[@b34-ndt-13-1741],[@b53-ndt-13-1741] This MPH-LA trial encompassed both fixed- and flexible dosing in a single patient cohort ([Figure 1](#f1-ndt-13-1741){ref-type="fig"}).[@b34-ndt-13-1741],[@b53-ndt-13-1741] This MPH-LA trial was a 40-week, randomized, double-blind, placebo-controlled, multicenter, efficacy and safety study of MPH-LA in the treatment of adult patients with childhood-onset ADHD. The primary objectives of the trial were to 1) confirm the clinically effective dose range; 2) confirm the maintenance effect of MPH-LA; and 3) evaluate safety profile of MPH-LA vs placebo. The three-phase study design also allowed for post hoc analysis of the benefits of dose optimization.[@b53-ndt-13-1741] Symptomatic and functional responses to MPH-LA were evaluated using validated instruments, including the *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS), and Sheehan Disability Scale (SDS).[@b66-ndt-13-1741],[@b67-ndt-13-1741] Published results demonstrate that dose optimization of MPH-LA is possible, sudden switching between doses is safe, dose optimization with MPH-LA (40, 60, or 80 mg/day) improves symptomatic and functional treatment outcomes, and numerous doses of MPH-LA are required for optimal treatment of adult ADHD.[@b34-ndt-13-1741],[@b53-ndt-13-1741]

Few other studies have also included an initial fixed-dose period followed by MPH dose optimization; however, these studies have not assessed the benefits of dose optimization. Wigal et al reported that pediatric patients continued to improve during an 11-week dose-optimization phase (open-label period).[@b38-ndt-13-1741] In addition, Buitelaar et al reported that following a 7-week open-label extension of the fixed-dose LAMDA study with a flexible dose of OROS-MPH dose (18--90 mg/day), ADHD patients experienced improvements in symptoms, ability to function, and quality of life.[@b54-ndt-13-1741],[@b68-ndt-13-1741] This was irrespective of whether they received placebo or OROS-MPH during the fixed-dose phase.

Optimized dosing: clinical efficacy and functional improvement in the MPH-LA trial
----------------------------------------------------------------------------------

Here we present previously unpublished post hoc analysis from the MPH-LA clinical trial ([Figures 2](#f2-ndt-13-1741){ref-type="fig"} and [3](#f3-ndt-13-1741){ref-type="fig"}; [Table 2](#t2-ndt-13-1741){ref-type="table"}).[@b34-ndt-13-1741] This post hoc analysis was conducted using the analysis of covariance model, with treatment and center as factors and baseline score as a covariate, to assess the benefits of dose optimization. DSM-IV ADHD RS and SDS scores were retrospectively analyzed for Period 1 based on patients' optimal dose, as determined during Period 2. Patients were then divided into four groups: placebo, patients who received their optimal dose, patients who received more than their optimal dose, and patients who received less than their optimal dose during Period 1 ([Figure 3A and B](#f3-ndt-13-1741){ref-type="fig"}).

Patients who received their optimal dose of MPH-LA during Period 1 exhibited the highest average improvements in DSM-IV ADHD RS and SDS total scores from baseline ([Figure 3A and B](#f3-ndt-13-1741){ref-type="fig"}, respectively). The highest improvement in DSM-IV ADHD RS ([Figure 3A](#f3-ndt-13-1741){ref-type="fig"}) was seen in patients who received their optimal dose (18.99: *P*\<0.0001 vs placebo), followed by patients who received greater than their optimal dose (17.78: *P*\<0.0001 vs placebo), and then those who received less than their optimal dose (14.10: *P*=0.0093 vs placebo). The improvement from baseline in SDS total score ([Figure 3B](#f3-ndt-13-1741){ref-type="fig"}) was greater in patients who received their optimal dose (7.41: *P*\<0.0001 vs placebo) compared with those who received more than their optimal dose (6.86: *P*=0.0003 vs placebo) and those who received less than their optimal dose (5.28: *P*=0.0506 vs placebo) during Period 1.

Optimized dose: safety profile of MPH in the MPH-LA trial
---------------------------------------------------------

MPH treatment is associated with several challenges, including high rates of mild-to-moderate AEs, poor compliance, high treatment discontinuation rates, and high rates of intersubject variability in response. A systematic review of literature revealed that AEs are one of the most common reasons for treatment discontinuation.[@b60-ndt-13-1741] The most common AEs reported with MPH included headaches, decreased appetite, dry mouth, nasopharyngitis, nausea, irritability, and insomnia.[@b34-ndt-13-1741],[@b54-ndt-13-1741] A recent meta-analysis revealed that MPH treatment was associated with an increased risk of nonserious AEs compared to placebo, but no increase in the risk of serious AEs.[@b69-ndt-13-1741] As with treatment efficacy, the relationship between dose and AEs remains unclear. In numerous MPH trials, a similar incidence of AEs, with the exception of decreased appetite and insomnia, was observed at all treatment doses.[@b34-ndt-13-1741],[@b37-ndt-13-1741] Moreover, the safety profile of MPH seems to be similar in pediatric and adult populations.[@b70-ndt-13-1741]

For the purpose of this review, AEs in Period 1 of the Huss et al MPH-LA study were reanalyzed based on patients' known optimal dose from Period 2.[@b34-ndt-13-1741] Descriptive statistics were used for the AE data, and [Table 2](#t2-ndt-13-1741){ref-type="table"} summarizes the proportion of AEs that occurred in ≥5% of patients. Patients who received more than their optimal dose experienced the highest rate of AEs (82.8% of patients) compared with those who received their optimal dose (68.3%) or less than their optimal dose (68.0%). Moreover, the rate of cardiac disorders (palpitations and tachycardia) seemed to be associated with the individually optimized dose: 19.8% of patients who received greater than their optimal dose experienced cardiac AEs compared with 10.6% of patients who received their optimal dose and 4.8% of patients who received less than their optimal dose ([Table 2](#t2-ndt-13-1741){ref-type="table"}). In addition, the proportion of patients who experienced decreased appetite was higher for those who received more than their optimal dose (35.3%) than for patients who received their optimal dose (25.2%) or less than their optimal dose (19.2%). There was no association between AEs and optimal dose for gastrointestinal disorders, general disorders (fatigue and irritability), infections and infestations, musculoskeletal and connective tissue disorders, skin disorders, or central nervous system disorders ([Table 2](#t2-ndt-13-1741){ref-type="table"}).

Discussion and limitations
==========================

There are limited data available regarding stimulant dose optimization versus fixed-dose regimens for ADHD. The MPH-LA study provides valuable insights into the clinical efficacy and safety benefits of optimized dosing; however, it was not specifically designed to assess this objective, and further research is needed to confirm the efficacy and safety benefits of dose optimization with MPH.[@b34-ndt-13-1741] Although dose optimization is reported in the majority of clinical trials and naturalistic studies, there is currently no data available regarding the use of dose optimization in general practice. Additionally, although the once-daily dosing regimen used in the MPH-LA adult study is optimal for scientifically investigating dosage, it does not mimic naturalistic real-world treatment regimens. As a result, there is a need to generate real-world data on the use of flexible dose in routine clinical practice. Murray and colleagues identified 13 electronic databases of ADHD health care records in Europe.[@b62-ndt-13-1741] In the future, these databases may provide additional insight into the long-term outcomes of ADHD patients.

This review has a number of potential limitations including that it was not a systematic literature review, and hence, the quality of the studies included in the review was not analyzed systematically. Although an extensive database was searched to identify relevant articles for inclusion, study inclusion may have been subject to the author and publication bias. Moreover, the methods of treatment optimization varied in different studies, which may impact the results; however, this was not considered while summarizing results in this review.

Conclusion
==========

Dose optimization may improve patient satisfaction with stimulant therapy and could also enhance treatment effectiveness, patient compliance, and tolerability. The authors recommend that dose individualization should continue to be used (or implemented if not yet used) to improve patient functioning and reduce the social and economic burden of disease, in the pharmacological treatment of ADHD.
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![The MPH-LA trial design includes a combination of fixed-dose (Period 1) and flexible-dose (Period 2 and Period 3) periods in a single study to assess the efficacy of MPH-LA in adult ADHD and to identify the individualized optimal dose for patients. Reproduced from Huss M, Ginsberg Y, Tvedten T, et al. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. *Adv Ther*. 2014;31(1):44--65.[@b34-ndt-13-1741]\
**Abbreviations:** ADHD, attention-deficit/hyperactivity disorder; MPH-LA, methylphenidate modified release long-acting formulation.](ndt-13-1741Fig1){#f1-ndt-13-1741}

![Individualized optimal dose achieved at the end of the open-label, flexible-dose (Period 2) shown by randomized dose received in Period 1.\
**Abbreviation:** MPH-LA, methylphenidate modified-release long-acting formulation.](ndt-13-1741Fig2){#f2-ndt-13-1741}

![LS mean change in (**A**) DSM-IV ADHD RS (n=119, n=116, n=119, and n=118, respectively) and (**B**) SDS total (n=113, n=115, n=117, and n=113, respectively) score from baseline 1 to end of Period 1 by optimal dose achieved in Period 2. Data were analyzed using an analysis of covariance model with treatment and center as factors, and baseline score as a covariate. *P*-values correspond to each group versus placebo.\
**Abbreviations:** DSM-IV ADHD RS, *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition Attention-Deficit/Hyperactivity Disorder Rating Scale; LS mean, least square mean; MPH-LA, methylphenidate modified-release long-acting formulation; SDS, Sheehan Disability Scale.](ndt-13-1741Fig3){#f3-ndt-13-1741}

###### 

Methylphenidate Treatment Guidelines: International and National ADHD Treatment recommendations[a](#tfn1-ndt-13-1741){ref-type="table-fn"}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Guidelines (country; year)                                                                   Treatment recommendations
  -------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  AAP Guidelines (US; 2011)[@b31-ndt-13-1741]                                                  Children and adolescents[b](#tfn2-ndt-13-1741){ref-type="table-fn"}:\
                                                                                               Clinicians should titrate doses of medication to achieve maximum benefit with minimum adverse effects

  BAP Guidelines (Great Britain; 2007, updated in 2014)[@b71-ndt-13-1741],[@b72-ndt-13-1741]   Children, adolescents, and adults:\
                                                                                               For immediate- or modified-release preparations of methylphenidate, titration to the optimal dose should take place over a 4- to 6-week period (maximum dose of 60 mg/day for adolescents and children; and 100 mg/day for adults)

  CADDRA Guidelines (Canadian; 2011)[@b30-ndt-13-1741]                                         Children, adolescents, and adults[c](#tfn3-ndt-13-1741){ref-type="table-fn"}:\
                                                                                               Clinicians should start with low doses of medication and slowly increase the dose until the optimal[d](#tfn4-ndt-13-1741){ref-type="table-fn"} treatment dose is reached

  ESCAP Guidelines (European Guidelines; 2004)[@b73-ndt-13-1741]                               Children, adolescents, and adults[e](#tfn5-ndt-13-1741){ref-type="table-fn"}:\
                                                                                               Clinicians should initiate treatment at a low dose (0.2 mg/kg/dose for children and adolescents) and treatment should be increased until a good result is achieved, or adverse effects appear, or the maximum dose is reached (0.7 mg/kg/dose for children and adolescents) -- whichever comes first

  New Zealand Ministry of Health Guidelines (2001)[@b49-ndt-13-1741]                           Children, adolescents, and adults[f](#tfn6-ndt-13-1741){ref-type="table-fn"}:\
                                                                                               Dosage should be individually titrated, starting at the lower end of the dose range (about 0.1--0.2 mg/kg). The dosage should be raised as needed (up to 60 mg/day for children and adolescents), and at a pace that will vary with the intensity depending on treatment effect and side effects\
                                                                                               Dosage should be maintained at the smallest dose for optimal[g](#tfn7-ndt-13-1741){ref-type="table-fn"} therapeutic response

  Malaysian Guidelines (2008)[@b74-ndt-13-1741]                                                Children, adolescents, and adults[h](#tfn8-ndt-13-1741){ref-type="table-fn"}:\
                                                                                               Dose titration, starting at the lower end of the dose range (2.5 mg/day, aged 3--5 years; 5 mg/day, aged 8 years; 10 mg/day, aged \>8 years), should be used to achieve the highest efficacy with minimal side effects (maximum dosage up to 60 mg/day; up to 30 mg/day, aged 3--5 years)[i](#tfn9-ndt-13-1741){ref-type="table-fn"}

  NICE Guidelines (England and Wales; updated 2016)[@b29-ndt-13-1741]                          Children and adolescents:\
                                                                                               Initial treatment with methylphenidate should begin with low doses of immediate-release (5 mg twice or three times, daily) or modified-release preparations[j](#tfn10-ndt-13-1741){ref-type="table-fn"}\
                                                                                               The dose should be titrated against symptoms and side effects over 4--6 weeks until dose optimization is achieved (maximum dosage up to 60 mg/day)\
                                                                                               Adults:\
                                                                                               Initial treatment should begin with low doses (5 mg three times daily for immediate-release preparations; the equivalent dose for modified-release preparations)\
                                                                                               The dose should be titrated against symptoms and side effects over 4--6 weeks and the dose should be increased according to response (maximum dose of 100 mg/day)

  NHMRC Guidelines (Australian; 2012)[@b75-ndt-13-1741]                                        Children and adolescents:\
                                                                                               Treatment and dosage must be tailored effectively to the individual needs of the child/adolescent

  SIGN Guidelines (Scottish; 2009)[@b76-ndt-13-1741]                                           Children and adolescents:\
                                                                                               Clinicians should follow a structured titration protocol so that the optimum dose of medication is established

  Spanish Guidelines (2010)[@b77-ndt-13-1741]                                                  Children and adolescents:\
                                                                                               Clinicians should start with low doses (2.5 or 5 mg depending on the child's weight; 2--3 times daily) of immediate-release methylphenidate\
                                                                                               The dose should be increased progressively (2.5--5 mg a week depending on the clinical response and presence of side effects) to a maximum dose of 60 mg/day

  Swedish Guidelines (2016)[@b42-ndt-13-1741]                                                  Children and adolescents:\
                                                                                               Clinicians should initiate treatment at a low dose (18 mg for long-acting; 5--10 mg for intermediate-acting) and adjust the dose incrementally (approximately once per week) until a dose that provides good effect and is well tolerated is reached[k](#tfn11-ndt-13-1741){ref-type="table-fn"}\
                                                                                               Adults:\
                                                                                               Clinicians are advised to begin treatment at a low dose and gradually increase (usually on a weekly basis) it to a dose that provides the best balance between efficacy and adverse effects (maximum dosage up to 80 mg/day)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Published guidelines available in English have been included in this table.

Pharmacological intervention is not recommended as a first-line treatment for preschool-age children (aged \<6 years).

Treatment before the age of 6 years, if necessary, should only be done under the direction of a specialist.

Optimal treatment means that the symptoms have decreased and that there is improvement in general functioning. Optimal dose is also that dose above which there is no further improvement. Sometimes side effects limit the dose titration.

Careful and detailed titration of dosage and timing is likely to improve response.

Treatment for adults, if necessary, should only be done under the direction of a specialist.

Titration schedules for specific pharmacological treatments are presented in the CADDRA Guidelines.

Optimal treatment depends on the balance of best improvement of the most significant problem, relatively lesser effect on other problems and existence of any side effects.

Dosage is usually not calculated based on body weight; however, the dosage range based on the body weight may be a guide during titration.

Dosage should be consistent with starting doses in the BNF.

Dose escalation should not be interrupted too early. It may be better to try a higher dose that can be reduced if adverse effects occur in order to achieve an optimal balance between efficacy and adverse effects.

**Abbreviations:** AAP, American Academy of Pediatrics; ADHD, attention-deficit/hyperactivity disorder; BAP, British Association for Psychopharmacology; BNF, British National Formulary; CADDRA, Canadian ADHD Resource Alliance; ESCAP, European Society for Child and Adolescent Psychiatry; AD, not applicable; NICE, National Institute for Health and Care Excellence; NIMH, National Institute of Mental Health; NHMRC, National Health and Medical Research Council; SIGN, Scottish Intercollegiate Guidelines Network.

###### 

Frequency of adverse events in Period 1 based on optimal dose achieved in Period 2

  Preferred term                                        MPH-LA in Period 1=optimal dose (N=123)   MPH-LA in Period 1\> optimal dose (N=116)   MPH-LA in Period 1\< optimal dose (N=125)   Placebo (N=125)
  ----------------------------------------------------- ----------------------------------------- ------------------------------------------- ------------------------------------------- -----------------
  **Total AEs**                                         84 (68.3)                                 96 (82.8)                                   85 (68.0)                                   70 (56.0)
  **Cardiac disorders**                                 13 (10.6)                                 23 (19.8)                                   6 (4.8)                                     1 (0.8)
  Palpitations                                          8 (6.5)                                   14 (12.1)                                   3 (2.4)                                     1 (0.8)
  Tachycardia                                           5 (4.1)                                   10 (8.6)                                    3 (2.4)                                     0 (0.0)
  **Gastrointestinal disorders**                        44 (35.8)                                 45 (38.8)                                   45 (36.0)                                   18 (14.4)
  Abdominal (upper) pain                                4 (3.3)                                   6 (5.2)                                     5 (4.0)                                     6 (4.8)
  Diarrhea                                              3 (2.4)                                   6 (5.2)                                     1 (0.8)                                     7 (5.6)
  Dry mouth                                             29 (23.6)                                 26 (22.4)                                   24 (19.2)                                   1 (0.8)
  Nausea                                                13 (10.6)                                 15 (12.9)                                   9 (7.2)                                     7 (5.6)
  **General disorders and administration conditions**   20 (16.3)                                 23 (19.8)                                   20 (16.0)                                   20 (16.0)
  Fatigue                                               7 (5.7)                                   10 (8.6)                                    8 (6.4)                                     8 (6.4)
  Irritability                                          6 (4.9)                                   8 (6.9)                                     6 (4.8)                                     7 (5.6)
  **Infections and infestations**                       19 (15.4)                                 28 (24.1)                                   25 (20.0)                                   25 (20.0)
  Nasopharyngitis                                       11 (8.9)                                  14 (12.1)                                   11 (8.8)                                    11 (8.8)
  **Investigations**                                    11 (8.9)                                  11 (9.5)                                    8 (6.4)                                     3 (2.4)
  **Metabolism and nutrition disorders**                31 (25.2)                                 41 (35.3)                                   24 (19.2)                                   9 (7.2)
  Decreased appetite                                    31 (25.2)                                 41 (35.3)                                   24 (19.2)                                   5 (4.0)
  **Musculoskeletal and connective tissue disorders**   8 (6.5)                                   11 (9.5)                                    7 (5.6)                                     7 (5.6)
  **Nervous system disorders**                          43 (35.0)                                 34 (29.3)                                   34 (27.2)                                   32 (25.6)
  Dizziness                                             6 (4.9)                                   9 (7.8)                                     7 (5.6)                                     5 (4.0)
  Headache                                              25 (20.3)                                 25 (21.6)                                   25 (20.0)                                   20 (16.0)
  **Psychiatric disorders**                             41 (33.3)                                 42 (36.2)                                   23 (18.4)                                   18 (14.4)
  Anxiety                                               6 (4.9)                                   7 (6.0)                                     1 (0.8)                                     0 (0.0)
  Initial insomnia                                      6 (4.9)                                   9 (7.8)                                     6 (4.8)                                     2 (1.6)
  Insomnia                                              11 (8.9)                                  10 (8.6)                                    3 (2.4)                                     6 (4.8)
  Restlessness                                          6 (4.9)                                   6 (5.2)                                     1 (0.8)                                     5 (4.0)
  Sleep disorder                                        7 (5.7)                                   1 (0.9)                                     1 (0.8)                                     2 (1.6)
  **Skin and subcutaneous tissue disorders**            14 (11.4)                                 15 (12.9)                                   9 (7.2)                                     8 (6.4)
  Hyperhidrosis                                         11 (8.9)                                  14 (12.1)                                   7 (5.6)                                     4 (3.2)

**Notes:** Data are presented as n (%). A patient with multiple occurrences of an AE under one treatment is counted only once in the AE category.

**Abbreviations:** AE, adverse event; MPH-LA, methylphenidate modified-release long-acting formulation.
